Multifocal hepatic neoplasia in 3 children with APC gene mutation

American Journal of Surgical Pathology

Volumn 37, Issue 7, 2013, Pages 1058-1066

  Gupta, Anita ^a   Sheridan, Rachel M ^a   Towbin, Alexander ^b   Geller, James I ^c   Tiao, Gregory ^d   Bove, Kevin E ^a,d  

^a Departments of Pathology   (United States)

^b Departments of Radiology   (Poland)

^c Departments of Orthopaedic Surgery and Oncology   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

2 hit Knudson hypothesis; APC gene mutation; Familial adenomatous polyposis; Hepatic adenoma; Hepatoblastoma

Indexed keywords

BETA CATENIN; GLUTAMATE AMMONIA LIGASE; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

ADENOMA; ARTICLE; CASE REPORT; FEMALE; GENETICS; HEPATOBLASTOMA; HUMAN; INFANT; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; METABOLISM; MULTIPLE CANCER; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOMA; BETA CATENIN; FEMALE; GENES, APC; GERM-LINE MUTATION; GLUTAMATE-AMMONIA LIGASE; GLYPICANS; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASMS, MULTIPLE PRIMARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84880293320     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31828aeb18     Document Type: Article

References (55)

1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
2. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr. 2005;147:263-266.
3. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist. 2008;13:812-820.
4. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132:398-400.
5. Curia MC, Zuckermann M, De Lellis L, et al. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol. 2008;21:7-14.
6. Hughes, Michels V. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992;43:1023-1025.
7. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999;59:269-273.
8. Giardiello FM, Petersen GM, Brensinger JD, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut. 1996;39:867-869.
9. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer. 2006;47:811-818.
10. O'Sullivan MJ, McCarthy TV, Doyle CT. Familial adenomatous polyposis: from bedside to benchside. Am J Clin Pathol. 1998; 109:521-526.
11. Bioulac-Sage P, Laumonier H, Kaurent C, et al. Hepatocellular adenoma: what is new in 2008. Hepatol Int. 2008;2:316-321.
12. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740-748.
13. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515-524.
14. Cadoret A, Ovejero C, Terris B, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002;21:8293-8301.
15. Su LK, Abdalla EK, Law CH, et al. Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer. 2001;92:332-339.
16. Roebuck Derek J, Aronson Daniel, Clapuyt Philippe, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37:123-132.
17. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135-140.
18. Knudson AG Jr., Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst. 1972;48: 313-324.
19. Knudson AG Jr., Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet. 1972;24:514-532.
20. Knudson AG Jr., Meadows AT, Nichols WW, et al. Chromosomal deletion and retinoblastoma. N Engl J Med. 1976;295:1120-1123.
21. Rashid A, Gao YT, Bhakta S, et al. Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res. 2001;61:3406-3409.
22. Bala S, Wunsch PH, Ballhausen WG. Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. Gastroenterology. 1997;112:919-922.
23. Takayasu H, Motoi T, Kanamori Y, et al. Two case reports of childhood liver cell adenomas harboring beta-catenin abnormalities. Hum Pathol. 2002;33:852-855.
24. Gruner BA, DeNapoli TS, Andrews W, et al. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol. 1998;20: 274-278.
25. Kurahashi H, Takami K, Oue T, et al. Biallelic inactivation of the APC gene in hepatoblastoma. Cancer Res. 1995;55:5007-5011.
26. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol. 2002;39:530-535.
27. Wei Y, Van Nhieu JT, Prigent S, et al. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology. 2002;36:692-701.
28. Blaker H, Hofmann WJ, Rieker RJ, et al. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer. 1999;25:399-402.
29. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med. 2011;135:704-715.
30. Jeannot E, Wendum D, Paye F, et al. Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. J Hepatol. 2006;45:883-886.
31. Toiyama Y, Inoue Y, Yasuda H, et al. Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: Report of a case. Surg Today. 2011; 41:1442-1446.
32. Armengol C, Cairo S, Fabre M, et al. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol. 2011;43:265-270.
33. Ló pez-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol. 2009;40:783-794.
34. Wei Y, Fabre M, Branchereau S, et al. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene. 2000;19: 498-504.
35. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48:163-170.
36. Bioulac-Sage P, Blanc JF, Rebouissou S, et al. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol. 2007;13:2649-2654.
37. Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26:774-780.
38. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95:8847-8851.
39. Nhieu JT, Renard CA, Wei Y, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155:703-710.
40. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Focal nodular hyperplasia, hepatocellular adenomas: past, present, future. Gastroenterol Clin Biol. 2010;34:355-358.
41. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009;50:746-754.
42. Wanless I, Callea F, Craig J, et al. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology. 1995;22:983-993.
43. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725-734.
44. Matsuno T, Goto I. Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res. 1992;52:1192-1194.
45. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132:1723-1728.
46. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558-564.
47. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008;39:224-230.
48. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol. 2001;23:496-499.
49. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97.
50. Sung YK, Hwang SY, Park MK, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003;94:259-262.
51. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125-129.
52. Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009;34:649-656.
53. Levy M, Trivedi A, Zhang J, et al. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol. 2012;43:695-701.
54. Ranganathan S, Tan X, Monga SP. Beta-catenin and met deregulation in childhood hepatoblastomas. Pediatr Dev Pathol. 2005;8:435-447. 54.
55. Montalto G, Cetta F, Baldi C, et al. Wide range of primary liver tumors can be found in patients with familial adenomatous polyposis. J Pediatr Hematol Oncol. 2000;22:90-91.